-+ 0.00%
-+ 0.00%
-+ 0.00%

AIM IMMUNOTECH SECURES BROAD U.S. PATENT FOR RINTATOLIMOD (AMPLIGEN®) USED IN COMBINATION WITH PEMBROLIZUMAB (KEYTRUDA®), EXPANDING ONCOLOGY IP PROTECTION FOR AMPLIGEN THROUGH 2039

Reuters·08/31/2026 12:51:07

Please log in to view news